Source disclosure: January 30, 2026
KISSEI PHARMACEUTICAL CO.,LTD. [4547.T]
TOKYO — Kissei Pharmaceutical Co., Ltd. reported its third quarter earnings for the fiscal year ending March 2026 on January 30, 2026. The company's consolidated results show mixed performance during the period from April 1, 2025 to December 31, 2025.
For the three months ended December 31, 2025, Kissei Pharmaceutical recorded a sales 633 billion, marking an increase of 10.6% compared to the same period last year. However, operating income declined sharply by 100%, turning negative at ¥3.682 billion against a positive ¥4.238 billion in the corresponding quarter of the previous year. Similarly, ordinary income also fell significantly, dropping to ¥2.226 billion from ¥5.298 billion in the prior-year period. Despite these declines, net income attributable to shareholders of the parent company improved by 24.6% to ¥11.014 billion from ¥8.840 billion in the same quarter last year.
Regarding the financial position as of December 31, 2025, the 607 billion, while equity increased slightly to ¥217.714 billion, resulting in a capital adequacy ratio of 83.4%. This is down from 85.6% in the previous fiscal year. Additionally, the book value per share rose to ¥5,220.29, up from ¥4,882.71 in the comparative period.
Kissei Pharmaceutical has revised its dividend forecast due to the commemorative dividend announced for its 80th anniversary. For the fiscal year ending March 2026, the interim dividend was set at ¥60 per share, which includes a regular dividend of ¥60 and a special commemorative dividend of ¥40. The final dividend is expected to be ¥100 per share, bringing the total annual dividend to ¥160 per share. This represents an increase from the previous year’s total dividend of ¥100 per share.
Looking ahead, Kissei Pharmaceutical forecasts full-year sales 500 billion for the fiscal year ending March 2026, representing an 8.1% growth over the previous year. Operating income is projected to decline further, showing a deficit of ¥2.600 billion, compared to a profit of ¥4.238 billion in the prior year. Ordinary income is anticipated to drop to a loss of ¥1.100 billion from a profit of ¥5.298 billion previously. Net income attributable to shareholders of the parent company is expected to reach ¥12.700 billion, indicating a modest 6.2% growth over the previous year. The earnings per share are estimated to rise to ¥305.56, reflecting the company's efforts to improve profitability despite challenging market conditions.
The company notes that no significant changes have been made to its accounting policies or estimates since the most recent disclosure. Furthermore, there were no material changes in the scope of consolidation for the current reporting period. Kissei Pharmaceutical emphasizes that the forward-looking statements provided in this report are based on assumptions about future events and may not reflect actual outcomes due to various uncertainties affecting business operations. Investors are advised to refer to additional information provided in the supplementary documents regarding the underlying assumptions and risks associated with the company's projections.
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms • Original filing